New antifungal drug fosmanogepix tested in healthy volunteers
NCT ID NCT06961708
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial studied the safety and how the body handles the experimental antifungal drug fosmanogepix in 54 healthy Chinese adults. Participants received single or multiple doses of the drug either by mouth or through an IV, or a placebo. The study measured drug levels in the blood and monitored for side effects to guide future dosing in patients with fungal infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fosmanogepix
- What this could lead to
- If successful, this study will provide key dosing and safety data for fosmanogepix, potentially supporting its use against serious fungal infections.
- What could go wrong
- This is an early Phase 1 trial in healthy volunteers, not patients. It only measures safety and drug levels, not whether the drug works against infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Xuhui Central Hospital, Longchuan North Road
Shanghai, 200237, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test